Evogene (NASDAQ:EVGN – Get Free Report) and Passage Bio (NASDAQ:PASG – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.
Analyst Ratings
This is a summary of current recommendations for Evogene and Passage Bio, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Evogene | 0 | 0 | 2 | 0 | 3.00 |
| Passage Bio | 0 | 0 | 4 | 0 | 3.00 |
Evogene currently has a consensus target price of $3.50, suggesting a potential upside of 157.35%. Passage Bio has a consensus target price of $7.50, suggesting a potential upside of 1,526.90%. Given Passage Bio’s higher possible upside, analysts plainly believe Passage Bio is more favorable than Evogene.
Risk and Volatility
Valuation and Earnings
This table compares Evogene and Passage Bio”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Evogene | $8.51 million | 0.86 | -$16.49 million | ($2.69) | -0.51 |
| Passage Bio | N/A | N/A | -$64.77 million | ($1.02) | -0.45 |
Evogene has higher revenue and earnings than Passage Bio. Evogene is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Evogene and Passage Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Evogene | -224.82% | -102.40% | -39.19% |
| Passage Bio | N/A | -93.59% | -59.65% |
Insider and Institutional Ownership
10.4% of Evogene shares are owned by institutional investors. Comparatively, 53.5% of Passage Bio shares are owned by institutional investors. 7.4% of Evogene shares are owned by company insiders. Comparatively, 5.0% of Passage Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Passage Bio beats Evogene on 8 of the 12 factors compared between the two stocks.
About Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
About Passage Bio
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
